IM Cannabis (NASDAQ: IMCC) is one of 43 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare IM Cannabis to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.
This table compares IM Cannabis and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IM Cannabis Competitors||-196.99%||-84.80%||-18.10%|
This table compares IM Cannabis and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|IM Cannabis||$11.86 million||-$21.42 million||-5.98|
|IM Cannabis Competitors||$220.78 million||-$89.53 million||-16.22|
IM Cannabis’ competitors have higher revenue, but lower earnings than IM Cannabis. IM Cannabis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings for IM Cannabis and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IM Cannabis Competitors||221||604||580||12||2.27|
IM Cannabis currently has a consensus target price of $8.75, suggesting a potential upside of 165.96%. As a group, “Medicinals & botanicals” companies have a potential upside of 43.87%. Given IM Cannabis’ stronger consensus rating and higher possible upside, research analysts plainly believe IM Cannabis is more favorable than its competitors.
Insider & Institutional Ownership
13.7% of IM Cannabis shares are held by institutional investors. Comparatively, 17.9% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 30.9% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
IM Cannabis beats its competitors on 8 of the 12 factors compared.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.